Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trials

Christopher Dasaro, Alyson Haslam, Vinay Prasad
doi: https://doi.org/10.1101/2024.02.05.24301181

Article Information

doi 
https://doi.org/10.1101/2024.02.05.24301181
History 
  • February 6, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Christopher Dasaro, BS1,*,
  2. Alyson Haslam, PhD2 and
  3. Vinay Prasad, MD, MPH2
  1. 1Lewis Katz School of Medicine at Temple University, 3500 N Broad St, Philadelphia, PA 19140
  2. 2Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158
  1. ↵*Corresponding author: Christopher Dasaro, BS, Lewis Katz School of Medicine at Temple University, 3500 N Broad St, Philadelphia, PA 19140 Email: tum91199{at}temple.edu
Back to top
Posted February 06, 2024.
Download PDF
Data/Code
Email
Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trials
Christopher Dasaro, Alyson Haslam, Vinay Prasad
medRxiv 2024.02.05.24301181; doi: https://doi.org/10.1101/2024.02.05.24301181
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area